Importantly, ER+ breast cancer cell lines were uniformly negative for GLP-1R, and immunotherapies are not currently approved for this subtype, suggesting that certain cancer subtypes could be safely treated with concurrent GLP-1RAs. Here, GLP1R is linked to breast carcinoma.